Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride

BACKGROUND: Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) leads to multiple metabolic changes, reduction in glucose levels and body weight are well established. In people with type 2 diabetes, GLP-1 RAs reduce the risk of cardiovascular (CV) disease and may also potentially re...

Descripción completa

Detalles Bibliográficos
Autores principales: Jendle, J., Hyötyläinen, T., Orešič, M., Nyström, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684205/
https://www.ncbi.nlm.nih.gov/pubmed/34920733
http://dx.doi.org/10.1186/s12933-021-01431-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684205/
https://www.ncbi.nlm.nih.gov/pubmed/34920733
http://dx.doi.org/10.1186/s12933-021-01431-2

Ejemplares similares